Management ChangeApr 16, 2026, 04:07 PM
Sensei Biotherapeutics: 3 Directors Tender Conditional Resignations
AI Summary
Sensei Biotherapeutics announced that three directors, Christopher W. Gerry, Thomas Ricks, and Kristian Humer, have tendered conditional resignations from the Board of Directors. These resignations are contingent upon stockholder approval of two key proposals at the upcoming Annual Meeting on June 10, 2026: the conversion of Series B Non-Voting Convertible Preferred Stock, which could result in a change of control, and an amendment to increase the authorized shares of common stock from 12.5 million to 300 million. The company stated that these resignations were not due to any disagreements regarding its operations.
Key Highlights
- Three directors, Christopher W. Gerry, Thomas Ricks, and Kristian Humer, tendered conditional resignations.
- Resignations are effective two business days after the Annual Meeting on June 10, 2026.
- Conditions include stockholder approval for Series B Preferred Stock conversion, potentially leading to a change of control.
- Also contingent on stockholder approval to increase authorized common stock from 12,500,000 to 300,000,000.